Pharmacology - Aug 16
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1- positive, metastatic non- small cell lung cancer and NTRK gene fusion- positive solid tumours
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1- positive, metastatic non- small cell lung cancer and NTRK gene fusion- positive solid tumours
wire - news in brief
« BACK
Pharmacology - Health - 16.08.2019
Health - Life Sciences - 15.08.2019 
Major award for two Bernese medical projects
Prestigious grants from the USA go to two Bernese researchers: the biomedical scientists Marianna Kruithof-de Julio and Robert Rieben were the only researchers in Switzerland to receive a grant under
Pharmacology - Health - 09.08.2019
Pharmacology - Health - 05.08.2019
Pharmacology - Health - 31.07.2019
Health - Psychology - 30.07.2019
Pharmacology - Health - 26.07.2019
Pharmacology - Health - 26.07.2019
Health - 24.07.2019
Health - Pharmacology - 22.07.2019
Life Sciences - Health - 21.07.2019 
150 years of DNA
DNA has become the icon of modern bioscience but few people realize that it was Friedrich Miescher, who - almost a century before Watson and Crick - laid the chemical groundwork for the molecular breakthroughs that followed. Today, 150 years after Miescher's first ‘discovery' of DNA, we want to highlight his remarkable work.
Health - 20.07.2019 
EPFLoop ready to roll in Los Angeles
The finals of the SpaceX Hyperloop Pod Competition will take place this Sunday. The crowning race will play out in an airless tube, and EPFL's student team is among the top three contenders.
Pharmacology - Health - 19.07.2019
Health - Pharmacology - 16.07.2019
Pharmacology - Health - 11.07.2019
Pharmacology - Health - 09.07.2019
Electroengineering - Health - 08.07.2019 
Wind power from the Sky
To harvest wind energy, you don't necessarily need rotors on steel masts - light kites on thin ropes can do the same. The Empa spin-off TwingTec has been researching this technology for some time now. Last autumn, it was possible for the first time to start, generate electrical energy while flying and then land again, all in the specified level of automation.
Health - Life Sciences - 08.07.2019
Health - 04.07.2019
Health - 04.07.2019
Life Sciences - Health - 03.07.2019
Health - Pharmacology - 02.07.2019
Pharmacology - Health - 02.07.2019
Pharmacology - Health - 01.07.2019
Pharmacology - Health - 01.07.2019
Pharmacology - Health - 01.07.2019
Health - Pharmacology - 28.06.2019
Health - 28.06.2019
Health - 26.06.2019
Career - Health - 24.06.2019 
Telephone-based coaching as an impetus for more exercise
Sports scientists from the University of Basel found that providing telephone-based coaching over the phone is an effective method for getting people in Switzerland to adopt a physically active lifestyle. Physical activity is a good way to minimize various health risks - regardless of gender, age and fitness level.
Pharmacology - Health - 24.06.2019
Life Sciences - Health - 21.06.2019
Health - Pharmacology - 18.06.2019
Health - 17.06.2019
Health - Pharmacology - 17.06.2019
Health - Pharmacology - 14.06.2019
Health - Pharmacology - 14.06.2019
Health - Social Sciences - 13.06.2019
Pharmacology - Health - 12.06.2019
Health - Pharmacology - 12.06.2019
Pharmacology - Health - 11.06.2019
Health - Life Sciences - 11.06.2019
Health - Pharmacology - 10.06.2019
Health - Pharmacology - 06.06.2019
Life Sciences - Health - 06.06.2019 
How flow shapes bacterial biofilms
EPFL biophysicists have taken a systematic look into how bacterial biofilms are affected by fluid flow. The findings can give us clues about the physical rules guiding biofilm architecture, but also about the social dynamics that shape evolution. Although we tend to think of them as solitary sojourners of the world, bacteria are actually very social organisms.
Health - Pharmacology - 06.06.2019
Health - Pharmacology - 04.06.2019
Pharmacology - Health - 04.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Health
Results 1 - 50 of 1581.
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
Prestigious grants from the USA go to two Bernese researchers: the biomedical scientists Marianna Kruithof-de Julio and Robert Rieben were the only researchers in Switzerland to receive a grant under
Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc
Roche and Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc.
Novartis receives positive CHMP opinion for Lucentis treatment
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years
DNA has become the icon of modern bioscience but few people realize that it was Friedrich Miescher, who - almost a century before Watson and Crick - laid the chemical groundwork for the molecular breakthroughs that followed. Today, 150 years after Miescher's first ‘discovery' of DNA, we want to highlight his remarkable work.
The finals of the SpaceX Hyperloop Pod Competition will take place this Sunday. The crowning race will play out in an airless tube, and EPFL's student team is among the top three contenders.
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of
To harvest wind energy, you don't necessarily need rotors on steel masts - light kites on thin ropes can do the same. The Empa spin-off TwingTec has been researching this technology for some time now. Last autumn, it was possible for the first time to start, generate electrical energy while flying and then land again, all in the specified level of automation.
CHMP recommends EU approval of Tecentriq for people with breast cancer
Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunother
Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunother
Sports scientists from the University of Basel found that providing telephone-based coaching over the phone is an effective method for getting people in Switzerland to adopt a physically active lifestyle. Physical activity is a good way to minimize various health risks - regardless of gender, age and fitness level.
Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Novartis Cosentyx first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
Cosentyx provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
EPFL biophysicists have taken a systematic look into how bacterial biofilms are affected by fluid flow. The findings can give us clues about the physical rules guiding biofilm architecture, but also about the social dynamics that shape evolution. Although we tend to think of them as solitary sojourners of the world, bacteria are actually very social organisms.
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar + Mekinist
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
Pharmacology - Aug 16
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1- positive, metastatic non- small cell lung cancer and NTRK gene fusion- positive solid tumours
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1- positive, metastatic non- small cell lung cancer and NTRK gene fusion- positive solid tumours